EXACT Therapeutics AS announces the publication of its 2021 Annual Report
Oslo/London – April 27th 2022: EXACT Therapeutics AS (“EXACT-Tx”, Euronext Growth: EXTX), a clinical stage biopharmaceutical company with a mission to enhance the therapeutic efficacy of medicines through ultrasound-mediated drug delivery, today announces that its Board of Directors has approved the Annual Report including the Annual Financial Statements for the year ended 31 December 2021.
The Annual Report for 2021 is also available on the Company's website: https://www.exact-tx.com/key-information
ENDS
For more information, please contact:
Dr Masha StrØmme, Executive Board Chair
EXACT Therapeutics
Email: Masha@exact-tx.com
Dominic Moreland, CFO
EXACT Therapeutics
Email: Dominic@exact-tx.com
Optimum Strategic Communications
Hollie Vile/ Manel Mateus/ Vici Rabbetts
Tel: +44 (0) 208 078 4357
Email: Exact@optimumcomms.com
About EXACT-Tx
EXACT-Tx is a Norwegian clinical-stage precision health company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® is a proprietary formulation of microclusters (PS101) activated by ultrasound for enhanced drug targeting deployed in multiple indications to enhance the therapeutic efficacy of medicines through the use of ultrasound-mediated drug delivery, for patients across multiple diseases. www.exact-tx.com
Forward looking statements
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by this forward-looking statement.